Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2021.02.24
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with ...
PDF (202 KB)
2021.02.22
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
PDF (131 KB)
2021.02.17
New Survey Reveals Nearly Half of Women Are Unfamiliar with a Condition that Affects Up to Five Mil ...
PDF (120 KB)
2021.02.03
HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with ...
PDF (180 KB)
2021.02.02
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research I ...
PDF (157 KB)
2021.01.29
Datopotamab Deruxtecan and ENHERTU® Show Promising Early Clinical Activity in Patients with Advance ...
PDF (326 KB)
2021.01.29
​​​​​​​New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutate ...
PDF (215 KB)
2021.01.27
ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society
PDF (335 KB)
2021.01.15
ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive A ...
PDF (325 KB)
2021.01.13
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment ...
Showing 1 - 10 of 43 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...